XML 78 R63.htm IDEA: XBRL DOCUMENT v3.24.0.1
Collaborative Arrangements - Master Collaboration and Research Agreement, Stock Purchase Agreement and Enzyme Supply Agreement (Details) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended
Jul. 31, 2022
Dec. 31, 2021
Jun. 30, 2020
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Investments in non-marketable securities       $ 1,191 $ 5,300 $ 7,630
Contract liabilities: deferred revenue       10,761 30,609  
Related Party            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Investments in non-marketable securities       0 0 7,630
MAI | Commercialization And Enzyme Supply Agreement            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Aggregate commercial sales, milestone     $ 5,000      
MAI | Master Collaboration & Research Agreement            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Revenue recognized from transactions         1,200 $ 2,000
MAI | Revenue sharing arrangement | Commercialization And Enzyme Supply Agreement            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Contract liabilities: deferred revenue     $ 500      
MAI | Product revenue | Master Collaboration & Research Agreement            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Revenue recognized from transactions       $ 200 $ 500  
MAI | Series A Preferred Stock            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Investment owned, balance (in shares)     1,587,050      
Investments in non-marketable securities     $ 1,000      
MAI | Series B Preferred Stock | Related Party            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Milestone payments received (in shares) 1,587,049 1,587,049        
MAI | Series A and B Preferred Stock | Master Collaboration & Research Agreement            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Investment owned, balance (in shares)   3,491,505     1,587,049 3,491,505
MAI Agreement | Related Party            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
MAI agreement milestone payment received $ 1,000 $ 1,000